HVTN一期临床试验参与者的物质使用模式:入组、风险降低咨询与保留
该Meta分析纳入2009年2月至2014年9月在美洲和瑞士开展的10项HVTN一期预防性HIV疫苗临床试验,共964名参与者,评估饮酒和吸毒对临床访视缺失、提前终止随访和疫苗接种完成的影响。结果显示,筛查时报告的饮酒频率、暴饮、大麻或其他药物使用与三项依从/保留指标均无关;暴饮与醉酒时无保护性行为率较高相关(p < .001)。轻至中度饮酒不影响一期临床试验的依从性或保留。
要点
- 964名参与者中170人(18%)错过一次临床访视,78人(8%)提前终止随访。
- 774名有多个疫苗接种时间点的参与者中75人(10%)未完成疫苗接种。
- 筛查时饮酒频率、暴饮、大麻或其他药物使用与依从/保留指标均无关。
核心结论
- 轻至中度饮酒不会对一期临床试验的依从性或保留产生负面影响。
- 基于筛查数据和试验期间参与者低感染率,HVTN一期试验的筛查流程在入组和保留低风险特征个体方面大体成功。
- 作者认为在风险降低咨询中关注暴饮及增加的HIV/性传播感染风险可能是合理的。
研究设计与样本
- 对2009年2月至2014年9月在美洲和瑞士开展的10项HVTN一期临床试验进行Meta分析。
- 纳入试验招募的是HIV感染风险特征较低的参与者,均使用相同的访谈员施测行为风险评估问卷,收集参与者自报过去六个月的物質使用情况。
- 共纳入964名参与者,使用卡方检验评估变量间的统计学差异。
主要发现
- 964名参与者中170人(18%)错过一次临床访视,78人(8%)提前终止临床随访。
- 774名有多个疫苗接种时间点的参与者中75人(10%)未完成疫苗接种。
- 筛查访视时报告的饮酒频率、暴饮、大麻或其他药物使用与三项依从/保留指标均无关。
- 暴饮与醉酒时无保护性行为率较高相关(p < .001)。
临床怎么用
- 作者认为在风险降低咨询中关注暴饮及增加的HIV/性传播感染风险可能是合理的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The primary objectives of HIV Vaccine Trials Network (HVTN) phase 1 preventive HIV vaccine clinical trials are to assess safety and immune response to study products. Participant alcohol and drug use may affect adherence, retention, and risk of HIV infection. Data on the effects of substance use are limited to medical care compliance and treatment adherence in HIV infected participants. To our knowledge, there are no data assessing substance use and retention in these vaccine trials. METHODS: We performed a meta-analysis on substance use and its impact on retention in HVTN phase I trials that recruited participants demonstrating lower risk profiles for HIV infection. Our analysis included data from 10 HVTN phase 1 clinical trials conducted between February 2009 and September 2014 in the Americas and Switzerland that utilized the identical interviewer-administered behavioral risk assessment questionnaire to capture participant self-report of substance use in the previous six months. Chi Square tests were used to assess statistical differences between variables. RESULTS: Among the 964 participants, 170 (18%) missed a clinic visit and 78 (8%) terminated early from clinic follow-up; 75/774 (10%) on studies with multiple vaccination timepoints did not complete their vaccinations. Neither frequency of alcohol use, binge drinking, marijuana, nor other drug use reported at screening visits were associated with the three adherence/retention measures. Binge drinking was associated with higher rates of unprotected sex while drunk (p < .001). CONCLUSIONS: Light to moderate alcohol use does not negatively impact adherence or retention in phase I clinical trials. Based on these screening data and the low infection rate of participants during the trial period, the screening process for participation in HVTN phase 1 trials has largely been successful in enrolling and retaining individuals with lower risk profiles. Focusing on binge drinking and increased HIV/STI risk during risk reduction counseling may be warranted.
引用
- Thiam-Diouf A, Metch B, Sharpe C, et al. Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention. Vaccine. 2018. PMID: 29395528. doi:10.1016/j.vaccine.2017.11.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。